http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Jian-Wei Dong,Le Cai,Xue-Jiao Li,Jia-Peng Wang,Rui-Feng Mei,Zhong-Tao Ding 대한약학회 2017 Archives of Pharmacal Research Vol.40 No.12
Three new monoterpene phenylpropionic acidesters, illigerates A–C (1–3), and one new aporphinealkaloid, illigeranine (4), as well as four known ones,actinodaphnine (5), nordicentrine (6), 8-hydroxy carvacrol(7), and 3-hydroxy-a,4-dimethyl styrene (8), were isolatedfrom the tubers of Illigera aromatica. The structures of 1–4were identified by HRESIMS, 1D and 2D NMR, andelectronic circular dichroism spectra. Compound 1 potentlyinhibited NO production in LPS-stimulated RAW264.7cells with an IC50 value of 18.71 ± 0.85 lM; compound 1,3, and 4 showed moderate butyrylcholinesterase inhibitoryactivities with the IC50 values of 46.86 ± 0.65,53.51 ± 0.71, and 31.62 ± 1.15 lM, respectively. Compound4 showed weak AChE inhibitory activity with anIC50 value of 81.69 ± 2.07 lM, and compounds 5 and 6possessed moderate AChE inhibitory activities with theIC50 values of 47.74 ± 1.66 and 40.28 ± 2.73 lM,respectively. This paper provides a chemical structure andbioactive foundation for using I. aromatica as an herbalmedicine.
Yang, Xiang-Di,Pan, Ling-Hui,Wang, Lin,Ke, Yang,Cao, Ji,Yang, Chun,Zhong, Jian-Hong,Luo, Wang,Guo, Jiao,Li, Le-Qun Asian Pacific Journal of Cancer Prevention 2015 Asian Pacific journal of cancer prevention Vol.16 No.13
Background: The role of surgical resection for patients with single large (${\geq}5cm$) and/or multinodular (${\geq}2$) hepatocellular carcinoma (HCC) is still controversial. This systematic review was performed to evaluate the safety and efficacy of resection for patients with single large and/or multinodular HCC. Materials and Methods: Databases (the PubMed, Web of Science, Embase, and Cochrane databases) were systematically searched to identify relevant studies exploring the safety and efficacy of resection for single large and/or multinodular HCC, published between January 2000 and December 2014. Perioperative morbidity and mortality, overall survival, and disease-free survival of the resection group were calculated. In addition, these outcome variables were also calculated for the control group in the included studies. Results: One randomized controlled trial and 42 nonrandomized studies involving 9,580 patients were eligible for analysis. Eight (1,594 patients) of the 43 studies also reported the outcomes of transarterial chemoembolization (TACE). Although 51.4% of patients featured cirrhosis, 90.7% of them demonstrated Child-Pugh A liver function in the resection group. The median rates of morbidity (24.5%) and mortality (2.5%) after resection were significantly higher than that of TACE (11.0%, P<0.001; 1.9%, P<0.001). However, patients who underwent resection had significantly higher median one-, three-, and five-year overall survival (76.1%, 51.7%, and 37.4%) than those who underwent TACE (68.3%, 31.5%, and 17.5%, all P<0.001). The median 1-, 3-, and 5-year DFS rates after resection were 58.3%, 34.6%, and 24.0%, respectively. Conclusions: Although tumor recurrence after resection for patients with single large and/ or multinodular HCC continues to be a major problem, resection should be considered as a strategy to achieve long-term survival.